The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
December 29th 2024
The top 5 ovarian cancer articles of 2024 covered topics such as the impact of air pollution on ovarian cancer risk, treatment strategies for patients with liver metastases, and the benefits of early diagnosis through symptom-triggered testing.
Chemotherapy Plus Cemiplimab Improves QOL vs Chemotherapy Alone in NSCLC
May 9th 2023An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.
Read More
Researchers Develop Prognostic Model for Survival in Patients With MF Undergoing Allo-HCT
May 8th 2023In addition to current available risk scores, the new system can help counsel patients with myelofibrosis (MF) undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT), authors wrote.
Read More
Study: Adding GLP1RA to T2D Therapy Linked With Lower MACE In Older Patients Without CVD
May 8th 2023Study authors said the findings could inform clinicians when selecting therapies for patients with type 2 diabetes (T2D). However, an editorial found the follow-up period too short and differences between the study arms too small to be meaningful.
Read More
Addressing Unmet Need: Could Children With Low-Grade Gliomas Have a New Treatment in Tovorafenib?
May 6th 2023For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.
Read More
Patients With Advanced Cancer With High TMB Show Favorable Outcomes on ICIs
May 5th 2023A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.
Read More
Despite Concerns Over Extrapolation, Bevacizumab Biosimilars Are Widely Used in mCRC
May 5th 2023A review article investigating the use of bevacizumab biosimilars found that despite lingering concerns about their usage for extrapolated indications, bevacizumab biosimilars are regularly used in metastatic colorectal cancer (mCRC) even though clinical tests only evaluate them in patients with lung cancer.
Read More
Research Explores Causes Behind Ineffective NO Treatment for Hypoxic Pulmonary Hypertension
May 5th 2023Researchers set out to examine the effects of sodium nitroprusside on the thromboxane-mediated contraction and nitric oxide (NO)-independent relaxation pathways and on reactive oxygen species accumulation in pulmonary artery smooth muscle cells.
Read More
Dr Jeffrey Lancet Discusses the Evolving Therapy Landscape of AML
May 4th 2023Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, gave insight on the evolving treatment landscape of acute myeloid leukemia (AML) and the potential of immunotherapy and targeted therapies going forward.
Watch
For Treatment Resistance in NSCLC, Repeat Biomarker Testing Is Key, Says Dr Mark Socinski
May 4th 2023Mark A. Socinski, MD, executive director of AdventHealth Cancer Institute, gave insight into treatment resistance and the importance of repeat biomarker testing at the time of disease progression in non–small cell lung cancer (NSCLC).
Watch
Iptacopan Meets Primary End Point of APPOINT-PNH Trial in Paroxysmal Nocturnal Hemoglobinuria
May 4th 2023Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.
Read More
Children of Mothers With HDP Have Greater Risk of Overall, Specific High Refractive Error
May 1st 2023A Danish study of nationwide registries estimated a 39% greater risk of high refractive error among children of mothers with hypertensive disorder of pregnancy (HDP), a complication that affects 5% to 10% of pregnancies.
Read More
Machine-Learning Approach Identifies 3 Behavioral Phenotypes of TLE
May 1st 2023Patients in this study, who had overall significantly higher scores than controls, fell into 3 categories of psychological risk from temporal lobe epilepsy (TLE) based on analysis with unsupervised machine learning.
Read More